AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Oncology Research Article
PDF (628.7 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Viewpoint | Open Access

The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma

GAVIN M. ANCHONDO, KYRA PARKER, ALEXIS BRUCE, ELIZABETH CORTEZ, LE SU( )
Department of Biology, Jacksonville State University, Jacksonville, AL36265, USA
Show Author Information

Abstract

Synovial sarcoma is a high-grade soft tissue malignancy characterized by a unique fusion gene known as SS18-SSX. The SS18-SSX fusion protein acts as an oncogenic driver of synovial sarcoma, and it has thus been commonly accepted that disruption of SS18-SSX function represents a therapeutic means of treating synovial sarcoma, but emerging evidence suggests that upon depletion of SS18-SSX, an anti-apoptotic signal surprisingly arises to protect synovial sarcoma cell survival. In this article, we discuss the controversial roles of SS18-SSX’s transcriptional activity in synovial sarcoma biology and outline a synergistic strategy for overcoming the resistance of synovial sarcoma cells to SS18-SSX targeted therapeutics.

Keywords

SS18-SSXSynovial sarcomaTargeted therapy

References

【1】
【1】
 
 
Crossref Google Scholar
Oncology Research
Volume 33 Issue 5,
April 2025
Pages 1001-1005
DOI: 10.32604/or.2025.060573

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
ANCHONDO GM, PARKER K, BRUCE A, et al. The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma. Oncology Research, 2025, 33(5): 1001-1005. https://doi.org/10.32604/or.2025.060573

432

Views

33

Downloads

7

Crossref

6

Web of Science

6

Scopus
Received: 05 November 2024
Accepted: 03 January 2025
Published: 18 April 2025
© The Author 2024.

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.